Advertisement

Picture Berlin Partner Events Bionnale 2025 May HealthCapital 650x100px
Organisation › Details

Halozyme Therapeutics Inc. (Nasdaq: HALO)

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched more than 800,000 patient lives in post-marketing use in eight commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals. Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals. Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility. *

 

Period Start 1998-01-01 established
  Group Halozyme (Group)
Products Industry biopharmaceutical
  Industry 2 drug delivery technology (drug formulation technology)
     
Region Region San Diego, CA
  Country United States (USA)
  Street 12390 El Camino Real
  City 92130 San Diego, CA
  Tel +1-858-794-8889
    Address record changed: 2024-11-20
     
Basic data Employees D: 101 to 500 (2024-02-12)
  Currency USD
  Annual sales 829,253,000 (revenues, total, consolidated (2023) 2023-12-31)
  Profit 281,594,000 (2023-12-31)
  Cash 326,000,000 (2023-12-31)
     
    * Document for »About Section«: Halozyme Therapeutics, Inc.. (11/14/24). "Press Release: Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction". San Diego, CA.
     
   
Record changed: 2024-11-23

Advertisement

Picture Swiss Biotech Association LSG Swiss Biotech Days 2025 Basel 650x200px

More documents for Halozyme (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner Voices Georg Duda Julius Wolff Institute 650x300px




» top